IQVIA Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Unlock the Full Value Chain Analysis for Deeper Insight
This IQVIA Value Chain Analysis gives you a structured view of how the company creates value through its support and primary activities. The page already includes a real preview of the actual analysis, so you can see the content and format before buying. Purchase the full version to get the complete ready-to-use report.
Support Activities
Firm Infrastructure
IQVIA's firm infrastructure links global governance, finance, legal, and compliance teams, which is vital for a business that serves sponsors in more than 100 countries. Its quality systems matter because it manages large volumes of sensitive health data under rules like HIPAA and GDPR. In FY2025, that control layer supported about $15.4 billion in revenue and 86,000+ employees.
Human Resource Management
In FY2025, IQVIA's human resource management supported a global team of about 88,000 people across 100+ countries, including clinical research associates, statisticians, data scientists, medical writers, and commercial specialists. Hiring and training these roles helps IQVIA keep trial quality high, shorten turnaround times, and deliver consistent execution across complex studies. That scale matters when 2025 revenue was about $15.4 billion.
Technology Development
In FY2025, IQVIA kept building analytics platforms, clinical trial software, and real-world evidence tools to join data across sources and automate trial work. That matters because IQVIA reported about $15.8 billion in revenue in 2025, showing scale for continued tech investment. These systems help speed study setup, cut manual steps, and improve evidence used by life sciences clients.
Procurement
IQVIA's procurement buys cloud capacity, software, data licenses, and specialist third-party services, so the firm can scale without heavy fixed assets. In 2025, cloud IT spending was forecast at $723.4 billion, which shows why sourcing well matters for cost control and speed.
Good procurement also lets IQVIA tap niche data and tech skills fast, instead of building every tool in-house. That supports its 2025 model across research, analytics, and clinical workflows, where vendor choice can affect margin and delivery time.
IQVIA's Global Engine Powers $15.8B in Revenue
IQVIA's support activities in FY2025 scaled its global controls, talent, technology, and sourcing across about 88,000 employees and more than 100 countries. That back office helped support about $15.8 billion in revenue while handling regulated health data and complex trials.
| Area | FY2025 |
|---|---|
| Revenue | $15.8B |
| Employees | ~88,000 |
| Countries | 100+ |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
IQVIA's inbound logistics starts with de-identified healthcare data, sponsor inputs, and site-level trial records, then cleans and standardizes them before use. In 2025, that matters because IQVIA's scale depends on turning fragmented clinical and real-world data into one governed pipeline for analytics and study execution. Strong data governance cuts errors, speeds trial setup, and helps sponsors trust the output. This front-end control is a core source of IQVIA's value.
Operations
IQVIA's 2025 operations center on clinical trial management, data analytics, real-world evidence studies, and commercial consulting, turning science and data into fee revenue. It ran work across more than 100 countries, which helps it support global sponsor trials and market access programs.
Its model scales because the same data assets can be reused across studies, so each new project adds margin with limited extra cost.
That mix made operations the main engine behind IQVIA's 2025 client delivery and revenue flow.
Outbound Logistics
IQVIA's outbound logistics moves dashboards, study databases, reports, and evidence packages to sponsors and other customers on tight timelines. In 2025, this step matters because life sciences delivery must be audit-ready, with clean version control, traceability, and secure handoff across regulated workflows. Fast, accurate delivery lowers study delay risk and helps sponsors use evidence quickly in filing, safety, and market access work.
Marketing and Sales
IQVIA's marketing and sales hinge on consultative, long-cycle enterprise deals with pharma, biotech, and medtech clients, not quick transactional selling. Buyers want proof of data scale, therapeutic depth, and delivery reliability, because contracts often tie into mission-critical analytics, clinical, and commercialization work.
That makes account teams, KOL (key opinion leader) reach, and renewal execution central to demand capture and retention.
Service
IQVIA's Service primary activity covers post-sale support such as study follow-up, query resolution, database lock support, and ongoing analytics. In 2025, this work helps reduce trial delays, improve data quality, and keep sponsors on contract for longer periods. It also supports post-market monitoring and commercial optimization, which is important as IQVIA serves life sciences clients in more than 100 countries.
IQVIA Turns Global Clinical Data Into Sponsor-Ready Evidence
In 2025, IQVIA's primary activities were clinical trial management, analytics, real-world evidence, commercial consulting, and secure delivery of study outputs. These steps turn de-identified data into sponsor-ready evidence across more than 100 countries, with scale improving reuse and margin.
| 2025 metric | Value |
|---|---|
| Countries served | 100+ |
| Main activity | Clinical and data services |
Get Your Copy
IQVIA Reference Sources
This is the actual IQVIA Value Chain Analysis document you'll receive upon purchase – no surprises, just professional quality. The preview below is pulled directly from the full report, so what you see is exactly what you get. Once you complete your purchase, the full in-depth version becomes available immediately.
Frequently Asked Questions
It starts with data acquisition, governance, and study planning. IQVIA pulls in healthcare data and sponsor requirements, then cleans and structures them before any trial or analytics work begins. That foundation matters because the company serves the full drug lifecycle, including 4 development phases and post-market surveillance, so early data quality shapes every downstream decision.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.